Edition:
United States

Zealand Pharma A/S (ZELA.CO)

ZELA.CO on Copenhagen Stock Exchange

84.50DKK
14 Dec 2017
Change (% chg)

kr.0.00 (+0.00%)
Prev Close
kr.84.50
Open
kr.84.00
Day's High
kr.85.50
Day's Low
kr.84.00
Volume
32,133
Avg. Vol
118,772
52-wk High
kr.141.00
52-wk Low
kr.82.00

Latest Key Developments (Source: Significant Developments)

Zealand Pharma Initiates Phase 3 Trial With Dasiglucagon
Thursday, 7 Dec 2017 09:36am EST 

Dec 7 (Reuters) - Zealand Pharma A/S ::ZEALAND PHARMA INITIATES THE PIVOTAL PHASE 3 TRIAL WITH DASIGLUCAGON FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA IN DIABETES.SAYS RESULTS FROM PHASE 3 TRIAL EXPECTED IN H2 2018​.  Full Article

Zealand Pharma Q3 operating loss at DKK 38.2 mln ​
Wednesday, 8 Nov 2017 09:00am EST 

Nov 8 (Reuters) - ZEALAND PHARMA A/S ::‍MAINTAINS ITS REVENUE GUIDANCE OF A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI.​.‍REVISED FINANCIAL GUIDANCE FOR 2017​.‍NET OPERATING EXPENSES IN 2017 ARE EXPECTED TO BE WITHIN RANGE OF DKK 375-385 MILLION, 4-6 % LOWER THAN PREVIOUSLY GUIDED​.‍NET OPERATING EXPENSES IN 2017 ARE EXPECTED TO BE WITHIN RANGE OF DKK 375-385 MILLION, 4-6 % LOWER THAN PREVIOUSLY GUIDED (DKK 390-410 MILLION).​.Q3 REVENUE DKK 40.1‍​ MILLION VERSUS DKK 39.6 MILLION YEAR AGO.2017 ‍OPERATING LOSS BEFORE ROYALTY INCOME/EXPENSES HAS BEEN REDUCED FROM DKK 290-310 MILLION TO DKK 275-285 MILLION​.‍FOR 2017, ZEALAND MAINTAINS ITS REVENUE GUIDANCE OF A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI​.Q3 OPERATING LOSS DKK 38.2 ‍​ MILLION VERSUS LOSS DKK 21.2 MILLION YEAR AGO.  Full Article

Zealand reports royalty revenue Of DKK 10.3 mln for Q3
Thursday, 2 Nov 2017 02:39am EDT 

Nov 2 (Reuters) - ZEALAND PHARMA A/S :REG- ZEALAND REPORTS ROYALTY REVENUE FOR THE THIRD QUARTER OF 2017.‍ZEALAND REPORTS ROYALTY REVENUE OF DKK 10.3 MILLION/USD 1.6 MILLION FOR Q3 2017​.  Full Article

Zealand Pharma granted orphan drug designation by FDA
Tuesday, 24 Oct 2017 06:43am EDT 

Oct 24 (Reuters) - ZEALAND PHARMA A/S ::REG-U.S. FDA GRANTS ORPHAN DRUG DESIGNATION TO GLEPAGLUTIDE FOR THE TREATMENT OF SHORT BOWEL SYNDROME.‍FDA OFFICE OF ORPHAN PRODUCTS DEVELOPMENT HAS GRANTED AN ORPHAN DRUG DESIGNATION TO GLEPAGLUTIDE​.  Full Article

Zealand Pharma Q2 operating loss widening to DKK 88.0 million
Thursday, 25 Aug 2016 01:55am EDT 

Zealand Pharma A/S : Q2 operating loss 88.0 million Danish crowns ($13.33 million) versus loss 64.6 million crowns year ago . Q2 revenue 7.9 million crowns versus 7.3 million crowns year ago . Financial guidance for 2016 unchanged .Maintains its revenue guidance for full-year.  Full Article

Zealand Pharma announces new timelines for U.S. FDA decision on iglarlixi
Friday, 19 Aug 2016 06:28pm EDT 

Zealand Pharma A/S : Zealand announces new timelines for a U.S. FDA decision on iglarlixi, the fixed-ratio combination of lixisenatide (adlyxintm) and lantus(r), for the treatment of type 2 diabetes . Financial guidance for 2016 remains unchanged . A U.S. regulatory decision on iglarlixi is now expected before end of November 2016 .FDA requested updated information on pen delivery device for iglarlixi as part of new drug application, which was submitted by Sanofi.  Full Article

Zealand Pharma: royalty revenue of DKK 6.4 mln in Q2 on sales of Lyxumia
Friday, 29 Jul 2016 01:36am EDT 

Zealand Pharma A/S : Lixisenatide as adlyxin to treat type 2 diabetes commercial launch by Sanofi in U.S. is expected later in H2 . Royalty revenue of 6.4 million Danish crowns ($950,000)/0.9 million euros in Q2 2016 on sales of Lyxumia(Lixisenatide outside U.S.) .US FDA approved recently lixisenatide as adlyxinto treat type 2 diabetes.  Full Article

Zealand Pharma and Beta Bionics to collaborate
Friday, 10 Jun 2016 09:00am EDT 

Zealand Pharma A/S : The company and Beta Bionics to collaborate on development of first-in-class dual-hormonal bionic pancreas system for treatment of people with type 1 diabetes . Financial guidance for 2016 remains unchanged . Synergistic match of Beta Bionics' dual-hormonal, artificial, or bionic, pancreas device platform, iLet, and Zealand’s liquid stable glucagon analog, ZP4207 . Expected next step under collaboration is initiation of clinical trials in H2 2016 .In future trials, the company will evaluate a multiple-dose version of its proprietary novel glucagon analog, ZP4207, with ilet.  Full Article

Sunstone's 13 pct stake in Zealand Pharma to be distributed to institutional investors
Thursday, 2 Jun 2016 05:59am EDT 

Zealand Pharma A/S : Says proposed voluntary liquidation of certain Sunstone managed funds during Q3 will lead to distribution of 13 pct of Zealand's share capital to broad group of institutional investors . Following liquidation, Sunstone will remain an 8.5 pct shareholder in Zealand .Has been informed that no single investor will receive more than 5 pct of share capital.  Full Article

Zealand says FDA votes for US approval of iGlarLixi
Wednesday, 25 May 2016 06:29pm EDT 

Zealand Pharma A/S : Says members of FDA advisory committee voted 12-2 for an approval of iGlarLixi . Says reiterates its financial guidance for 2016 . A decision by FDA is expected for lixisenatide in July 2016 and for iGlarLixi in August 2016. .Ratio combination of lixisenatide and Lantus(r).  Full Article

BRIEF-Zealand Pharma Initiates Phase 3 Trial With Dasiglucagon

* ZEALAND PHARMA INITIATES THE PIVOTAL PHASE 3 TRIAL WITH DASIGLUCAGON FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA IN DIABETES